Implications of protein post-translational modifications in IBD

Inflammatory Bowel Diseases

Volumn 18, Issue 7, 2012, Pages 1378-1388

  Ehrentraut, Stefan F ^a   Colgan, Sean P ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

IBD; Molecular mechanisms; Posttranslational protein modifications

Indexed keywords

CYTOKINE;

CYTOKINE PRODUCTION; ENTERITIS; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84862233291     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22859     Document Type: Review

References (121)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
2. Marks DJ, Rahman FZ, Sewell GW, et al. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38:20-31.
3. Barnes PJ, Karin M. Nuclear factor-jB-a pivitol transcription factor in chronic inflammatory disease. N Engl J Med. 1997;336:1066-1071. (Pubitemid 27163860)
4. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke. 2004;35: 1506-1518. (Pubitemid 38697484)
5. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995;9:1586-1597.
6. Brown K, Gerstberger S, Carlson L, et al. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267:1485-1488.
7. DiDonato JA, Hayakawa M, Rothwarf DM, et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388:548-554. (Pubitemid 27339997)
8. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature. 2007; 446:552-556. (Pubitemid 46514719)
9. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB- alpha ubiquitination. Science. 2000;289:1560-1563.
10. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104-112. (Pubitemid 38081475)
11. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119-144.
12. Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci. 2006;1072: 242-252. (Pubitemid 44448457)
13. Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006;22:85-89. (Pubitemid 44090070)
14. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999;116:301-309. (Pubitemid 29055352)
15. Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNF-alpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci. 1999;112(Pt 1):137-146. (Pubitemid 29043841)
16. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164-6172. (Pubitemid 37467239)
17. Wang F, Schwarz BT, Graham WV, et al. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006;131:1153-1163. (Pubitemid 44515106)
18. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol. 2006;169: 1901-1909. (Pubitemid 351181952)
19. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2006;290:G496-504.
20. Ma TY, Boivin MA, Ye D, et al. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol. 2005;288:G422-430. (Pubitemid 40261739)
21. Suzuki A, Ishiyama C, Hashiba K, et al. aPKC kinase activity is required for the asymmetric differentiation of the premature junctional complex during epithelial cell polarization. J Cell Sci. 2002; 115:3565-3573.
22. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J. 2003;370:361-371. (Pubitemid 36315124)
23. Gao T, Newton AC. Invariant Leu preceding turn motif phosphorylation site controls the interaction of protein kinase C with Hsp70. J Biol Chem. 2006;281:32461-32468. (Pubitemid 46036801)
24. Mashukova A, Oriolo AS, Wald FA, et al. Rescue of atypical protein kinase C in epithelia by the cytoskeleton and Hsp70 family chaperones. J Cell Sci. 2009;122:2491-2503.
25. Mashukova A, Wald FA, Salas PJ. Tumor necrosis factor alpha and inflammation disrupt the polarity complex in intestinal epithelial cells by a posttranslational mechanism. Mol Cell Biol. 2011;31:756-765.
26. Bossard C, Souaze F, Jarry A, et al. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis. Peptides. 2007;28:2030-2035. (Pubitemid 47419096)
27. Tsuchiya K, Nakamura T, Okamoto R, et al. Reciprocal targeting of Hath1 and beta-catenin by Wnt glycogen synthase kinase 3beta in human colon cancer. Gastroenterology. 2007;132:208-220. (Pubitemid 46108744)
28. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle. 2009;8:4032-4039.
29. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/ degradation by a dual-kinase mechanism. Cell. 2002;108: 837-847. (Pubitemid 34327534)
30. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14: 1837-1851. (Pubitemid 30639518)
31. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512. (Pubitemid 28425575)
32. Klamer G, Song E, Ko KH, et al. Using small molecule GSK3beta inhibitors to treat inflammation. Curr Med Chem. 2010;17:2873-2881.
33. Nava P, Koch S, Laukoetter MG, et al. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity. 2010;32:392-402.
34. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155-1161.
35. Kamitani T, Kito K, Nguyen HP, et al. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem. 1997;272:28557-28562. (Pubitemid 27517807)
36. Mikus P, Zundel W. COPing with hypoxia. Semin Cell Dev Biol. 2005;16:462-473. (Pubitemid 41247870)
37. Jones D, Crowe E, Stevens TA, et al. Functional and phylogenetic analysis of the ubiquitylation system in Caenorhabditis elegans: ubiquitin- conjugating enzymes, ubiquitin-activating enzymes, and ubiquitin- like proteins. Genome Biol. 2002;3:RESEARCH0002.
38. Osaka F, Saeki M, Katayama S, et al. Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J. 2000;19: 3475-3484. (Pubitemid 30428225)
39. Tateishi K, Omata M, Tanaka K, et al. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol. 2001;155:571-579. (Pubitemid 34289315)
40. Ou CY, Lin YF, Chen YJ, et al. Distinct protein degradation mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye development. Genes Dev. 2002;16:2403-2414.
41. Wada H, Kito K, Caskey LS, et al. Cleavage of the C-terminus of NEDD8 by UCH-L3. Biochem Biophys Res Commun. 1998;251: 688-692. (Pubitemid 28512771)
42. Huang DT, Miller DW, Mathew R, et al. A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nat Struct Mol Biol. 2004;11:927-935. (Pubitemid 39315295)
43. Mendoza HM, Shen LN, Botting C, et al. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J Biol Chem. 2003;278:25637-25643. (Pubitemid 36835317)
44. Wu K, Yamoah K, Dolios G, et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J Biol Chem. 2003;278:28882-28891. (Pubitemid 36935799)
45. Liakopoulos D, Doenges G, Matuschewski K, et al. A novel protein modification pathway related to the ubiquitin system. EMBO J. 1998;17:2208-2214. (Pubitemid 28171906)
46. Hori T, Osaka F, Chiba T, et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene. 1999; 18:6829-6834.
47. Jones J, Wu K, Yang Y, et al. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J Proteome Res. 2008;7:1274-1287.
48. Parry G, Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Semin Cell Dev Biol. 2004; 15:221-229. (Pubitemid 38251651)
49. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82:373-428. (Pubitemid 34654457)
50. Kumar A, Wu H, Collier-Hyams LS, et al. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J. 2007;26:4457-4466. (Pubitemid 350036625)
51. Eltzschig HK, Rivera-Nieves J, Colgan SP. Targeting the A2B adenosine receptor during gastrointestinal ischemia and inflammation. Expert Opin Ther Targets. 2009;13:1267-1277.
52. Khoury J, Ibla JC, Neish AS, et al. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J Clin Invest. 2007;117:703-711. (Pubitemid 46348528)
53. Mendoza HM, Shen LN, Botting C, et al. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J Biol Chem. 2003;278:25637-25643. (Pubitemid 36835317)
54. Wu K, Yamoah K, Dolios G, et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J Biol Chem. 2003;278:28882-28891. (Pubitemid 36935799)
55. Semenza GL. HIF-1, O (2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001;107:1-3. (Pubitemid 32972030)
56. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275. (Pubitemid 29246458)
57. Tanimoto K, Makino Y, Pereira T, et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19:4298-4309. (Pubitemid 30623741)
58. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science. 2002; 295:858-861. (Pubitemid 34118367)
59. Mikus P, Zundel W. COPing with hypoxia. Semin Cell Dev Biol. 2005;16:462-473. (Pubitemid 41247870)
60. Chiba T, Tanaka K. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr Protein Pept Sci. 2004;5:177-184. (Pubitemid 38647470)
61. Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol. 2003;19:261-286. (Pubitemid 37487350)
62. MacManus CF, Campbell EL, Keely S, et al. Anti-inflammatory actions of adrenomedullin through fine tuning of HIF stabilization. FASEB J. 2011;25:1856-1864.
63. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med (Berl). 2007;85:1295-1300. (Pubitemid 50004090)
64. Hatoum OA, Binion DG, Gutterman DD. Paradox of simultaneous intestinal ischaemia and hyperaemia in inflammatory bowel disease. Eur J Clin Invest. 2005;35:599-609. (Pubitemid 41406724)
65. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656-665.
66. Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med. 2010;2:336-361.
67. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
68. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009; 119:1159-1166.
69. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest. 2007;117:862-865. (Pubitemid 46556739)
70. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009; 119:1159-1166.
71. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30: 393-402. (Pubitemid 351681994)
72. Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology. 2008;134:156-165.
73. Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia- inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134:145-155. (Pubitemid 350309309)
74. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia- induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006; 103:18154-18159. (Pubitemid 44871628)
75. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365:537-547.
76. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-50-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 (HIF-1) mediates permeability changes in intestinal epithelia. J Clin Invest. 2002; 110:993-1002.
77. Han IO, Kim HS, Kim HC, et al. Synergistic expression of inducible nitric oxide synthase by phorbol ester and interferon-gamma is mediated through NF-kappaB and ERK in microglial cells. J Neurosci Res. 2003;73:659-669.
78. Karhausen JO, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia- inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098-1106. (Pubitemid 39578699)
79. Morote-Garcia JC, Rosenberger P, Nivillac NM, et al. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology. 2009;136:607-618.
80. Shah YM, Ito S, Morimura K, et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology. 2008;134:2036-2048, 2048 e2031-2033.
81. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209-213. (Pubitemid 36308037)
82. Mariani F, Sena P, Marzona L, et al. Cyclooxygenase-2 and Hypoxia- Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Lett. 2009;279:221-229.
83. Matthijsen RA, Derikx JP, Kuipers D, et al. Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. PLoS One. 2009;4:e7045.
84. Louis NA, Hamilton KE, Canny G, et al. Selective induction of mucin-3 by hypoxia in intestinal epithelia. J Cell Biochem. 2006;99: 1616-1627. (Pubitemid 44845721)
85. Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1- dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193:1027-1034. (Pubitemid 32436196)
86. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387-3394. (Pubitemid 34651384)
87. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198:783-796. (Pubitemid 37087777)
88. Mole DR, Schlemminger I, McNeill LA, et al. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Ned Chem Lett. 2003;13:2677-2680. (Pubitemid 36851548)
89. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O (2) levels. J Cell Sci. 2003; 116:3041-3049. (Pubitemid 37038953)
90. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010;7:281-287.
91. Tambuwala MM, Cummins EP, Lenihan CR, et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology. 2010;139: 2093-2101.
92. Hindryckx P, De Vos M, Jacques P, et al. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia- inducible factor-1-dependent repression of FADD. J Immunol. 2010;185:6306-6316.
93. Ting JP, Lovering RC, Alnemri ES, et al. The NLR gene family: a standard nomenclature. Immunity. 2008;28:285-287. (Pubitemid 351350631)
94. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol. 2008;20:3-9.
95. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest. 2009;119:3502-3511.
96. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319-325. (Pubitemid 38388233)
97. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417-426. (Pubitemid 35007355)
98. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.
99. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007;178:4641-4649. (Pubitemid 46492417)
100. Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007;14:1583-1589. (Pubitemid 47278844)
101. Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/ Nalp3. Nature. 2006;440:233-236. (Pubitemid 43372103)
102. Cruz CM, Rinna A, Forman HJ, et al. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem. 2007;282:2871-2879. (Pubitemid 47084344)
103. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269:15195-15203.
104. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59:1192-1199.
105. Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis. 2011;17:1359-1372.
106. Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32:367-378.
107. Zaki MH, Vogel P, Body-Malapel M, et al. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010;185:4912-4920.
108. Kanai T, Watanabe M, Okazawa A, et al. Macrophage-derived IL- 18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology. 2001;121:875-888. (Pubitemid 32959397)
109. Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A. 2001;98:13249-13254. (Pubitemid 33051348)
110. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin- 18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1264-1273.
111. Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379-391.
112. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
113. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140:1704-1712.
114. Bertin J, Guo Y, Wang L, et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem. 2000;275:41082-41086. (Pubitemid 32054936)
115. Ruland J. CARD9 signaling in the innate immune response. Ann N Y Acad Sci. 2008;1143:35-44.
116. Gross O, Poeck H, Bscheider M, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature. 2009;459:433-436.
117. Bi L, Gojestani S, Wu W, et al. CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination leading to activation of NF-kappaB in response to stimulation by the hyphal form of Candida albicans. J Biol Chem. 2010;285:25969-25977.
118. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727-1735.
119. Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82:1202-1210.
120. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446: 557-561. (Pubitemid 46514732)
121. Yang H, Minamishima YA, Yan Q, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell. 2007;28:15-27. (Pubitemid 47531976)